Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.45 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.43 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30292047 | 1.00 | MAPT (0.53) | MAPTALDH1A1KMT2AMEN1POLB | |
| SCHEMBL926287 | 0.88 | HSD17B10 (0.49) | MAPTALDH1A1KMT2AMEN1POLB | |
| SCHEMBL8347590 | 0.84 | GPR35 (0.47) | ALDH1A1KMT2AMEN1SMN1; SMN2IMPDH2 | |
| SCHEMBL16371752 | 0.82 | CYP3A4 (0.45) | MAPTALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL6170216 | 0.82 | AAK1 (0.55) | MAPTALDH1A1KMT2AMEN1POLB | |
| SCHEMBL5777364 | 0.82 | IMPDH2 (0.45) | MAPTALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL5774602 | 0.82 | AAK1 (0.45) | MAPTALDH1A1KMT2AMEN1POLB | |
| SCHEMBL6170663 | 0.82 | ALDH1A1 (0.49) | MAPTALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL30298789 | 0.82 | ALDH1A1 (0.49) | MAPTALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL30292049 | 0.82 | IMPDH2 (0.45) | MAPTALDH1A1KMT2AMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1186598-B1 | Process of preparing 5-(2-substituted-4-nitrophenyl)-oxazole, oxazole compound, and process of preparing the same | NIPPON SYNTHETIC CHEM IND (JP) | 2005-03-16 | — | — | EP | claimed |
| US-6423849-B1 | VIRICIDES; ANTICANCER AGENTS | THE NIPPON SYNTHETIC CHEMICAL INDUSTRY CO., LTD. (JP) | 2002-07-23 | — | — | US | claimed |
| US-20020035265-A1 | Process of preparing 5-(2-substituted-4-nitrophenyl)-oxazole, novel oxazole compound, and process of preparing the same | THE NIPPON SYNTHETIC CHEMICAL INDUSTRY CO., LTD. | 2002-03-21 | — | — | US | claimed |
| EP-1186598-A1 | Process of preparing 5-(2-substituted-4-nitrophenyl)-oxazole, oxazole compound, and process of preparing the same | The Nippon Synthetic Chemical Industry Co., Ltd. (JP) | 2002-03-13 | — | — | EP | claimed |
| US-12630542-B2 | Compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium | ENDOGENA THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12195452-B2 | N-(4-(oxazol-5-yl)phenyl) chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases | ENDOGENA THERAPEUTICS, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| EP-3902798-B1 | N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS INC (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-3902798-B1 | N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS INC (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230322749-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | ENDOGENA THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322749-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | ENDOGENA THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4167999-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | Endogena Therapeutics, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-115916192-A | Novel compounds and their use as therapeutically active substances for the treatment and/or prophylaxis of diseases in which the retinal pigment epithelium is involved | 内生疗法公司 | 2023-04-04 | — | — | CN | disclosed |
| WO-2020140050-A1 | N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| US-7329681-B2 | Inhibitors of IMPDH enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329681-B2 | Inhibitors of IMPDH enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1186598-B1 | Process of preparing 5-(2-substituted-4-nitrophenyl)-oxazole, oxazole compound, and process of preparing the same | NIPPON SYNTHETIC CHEM IND (JP) | 2005-03-16 | — | — | EP | disclosed |
| US-6423849-B1 | VIRICIDES; ANTICANCER AGENTS | THE NIPPON SYNTHETIC CHEMICAL INDUSTRY CO., LTD. (JP) | 2002-07-23 | — | — | US | disclosed |
| US-20020035265-A1 | Process of preparing 5-(2-substituted-4-nitrophenyl)-oxazole, novel oxazole compound, and process of preparing the same | THE NIPPON SYNTHETIC CHEMICAL INDUSTRY CO., LTD. | 2002-03-21 | — | — | US | disclosed |
| EP-1186598-A1 | Process of preparing 5-(2-substituted-4-nitrophenyl)-oxazole, oxazole compound, and process of preparing the same | The Nippon Synthetic Chemical Industry Co., Ltd. (JP) | 2002-03-13 | — | — | EP | disclosed |
| JP-2001011059-A | PRODUCTION OF 5-(2-SUBSTITUTED-4-NITROPHENYL)-OXAZOLE | NIPPON SYNTHETIC CHEM IND CO LTD:THE | 2001-01-16 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322749-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | ALDH1A2, NR2E3, RB1 | MAPT 1965/4885ALDH1A1 462/4885KMT2A 2849/4885 |
| US-20020035265-A1 | Process of preparing 5-(2-substituted-4-nitrophenyl)-oxazole, novel oxazole compound, and process of preparing the same | PNPO, OXA1L, ATIC | MAPT 2812/4885ALDH1A1 2039/4885KMT2A 1395/4885 |
| US-12630542-B2 | Compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium | ALDH1A2, NR2E3, GFRA1 | MAPT 1959/4885ALDH1A1 375/4885KMT2A 2819/4885 |
| US-12195452-B2 | N-(4-(oxazol-5-yl)phenyl) chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases | NR2E3, GFRA2, ALDH1A2 | MAPT 3219/4885ALDH1A1 1885/4885KMT2A 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.